Saturday, May 26, 2018
Perspective

Perspective: Why two Americans got Ebola treatment (w/video)

What should happen if a massive viral outbreak appears out of nowhere and the only possible treatment is an untested drug? And who should receive it?

The two American missionaries who contracted the almost-always-fatal virus in West Africa were given access to an experimental drug cocktail called ZMapp. It consists of immune-boosting monoclonal antibodies that were extracted from mice exposed to bits of Ebola DNA. Now in isolation at an Atlanta hospital, they appear to be doing well.

It's an opportunity the 900 Africans who've died so far never had. Is there a case to suspend ethical norms if lives might be saved by deploying an experimental drug?

The reasons for different treatment are partly about logistics, partly about economics and, partly about a lack of any standard policy for giving out untested drugs in emergencies. Before this outbreak, ZMapp had only been tested on monkeys.

Mapp, the tiny, San Diego based pharmaceutical company that makes the drug stated two years ago: "When administered one hour after infection (with Ebola), all animals survived. … Two-thirds of the animals were protected even when the treatment, known as Zmapp, was administered 48 hours after infection."

But privileged humans were always going to be the first ones to try it. ZMapp requires a lot of refrigeration and careful handling, plus close monitoring by experienced doctors and scientists — better to try it at a big urban hospital than in rural West Africa, where no such infrastructure exists.

And because of the drug's experimental nature, it's unclear that it should go to anyone else. Even if the drug is cooled correctly, success in a few monkeys (less than 20) tells us little about what will happen in a lot of humans who'd had the infection for more than two days.

No one knows how much drug to give, how often, what other pre-existing medical conditions might influence its efficacy or even what route is best, be it IV, pill, syrup, or even surgically right into the liver. With an untested drug, there is always a chance you will kill the first human subject who might otherwise have lived.

And the two Americans who got it in Africa had been infected for more than a week, making its efficacy completely unknown. Still, because they are a small group in such a carefully controlled setting, they are better candidates for the drug than others might be.

But it's about more than logistics. Drugs based on monoclonal antibodies usually cost a lot — at least tens of thousands of dollars, and a tiny company won't enthusiastically give away its small supply of drugs for free.

It is likely that if they were going to donate drugs, it would be to people who would command a lot of press attention and, thus, investors and government money for further research — which is to say, not to poor Liberians, Nigerians or Guineans.

The Americans got the experimental drug because the evangelical Christian International Relief organization they work for, Samaritan's Purse, reached out to the CDC and the NIH to see if there was any drug. They were referred to Mapp Pharmaceuticals and evidently struck some kind of deal to get the drug to their employees who were in Africa at the time.

The FDA has little oversight over what goes on abroad, and the federal government has no program to consider appeals for use — much less payment — of experimental drugs that have only been tried on animals. Without an organization pushing, no one might have received access to any sort of treatment. The chance of a poor African getting an experimental drug is about the same as Donald Trump contracting Ebola (which is apparently his greatest current fear).

There is no accepted set of rules for a sick person to request compassionate access to a drug that is experimental, expensive and in short supply. Access to experimental drugs remains a long shot full of risk. While most people would want to do something rather than nothing, the decision about gaining access is more in the hands of the drug manufacturer than the subject.

The dying may feel more cavalier about entering a drug experiment — the rewards (life) could justify the risks (since death approaches anyway) — but a company may still withhold a drug from a volunteer for fear that it will fail and reduce investor interest or increase attention from malpractice attorneys.

An ethical case can surely be made for an organization that puts health care workers in harm's way to acquire access to experimental drugs and bring staff home to get the best possible care. But that's neither fair nor just for deciding what to do when an emergency arises and rationing is the only option.

This Ebola outbreak has taught us two things: that we need to act quickly to shut down emerging epidemics wherever they occur, and it is long past time to have a transparent public policy about what to do when not everyone gets a chance to live.

Arthur L. Caplan is the director of the Division of Medical Ethics at New York University's Langone Medical Center's Department of Population Health.

© 2014 Washington Post

Comments
The real stuff is how Tom Wolfe best used his write stuff

The real stuff is how Tom Wolfe best used his write stuff

Tom Wolfe’s best writing lifted real people into legend: car designers and astronauts and disciples of LSD. With that writing, Wolfe lifted himself into legend as well. The author of 16 books, including such bestsellers as The Right Stuff and ...
Published: 05/18/18
Oh, Florida! Without air conditioning we’re a stinky swamp of sweat. With it, we warm the world

Oh, Florida! Without air conditioning we’re a stinky swamp of sweat. With it, we warm the world

As I write this, some workers are disassembling the 24-year-old air conditioning system in my house. They’re clunking and clanking around, tromping up and down my stairs, so they can replace the old system with a new one that presumably wonR...
Published: 05/17/18
Updated: 05/18/18
PolitiFact: Is Mike Pence right that religion is gaining new life in U.S.?

PolitiFact: Is Mike Pence right that religion is gaining new life in U.S.?

Speaking at a commencement ceremony at Hillsdale College in Michigan, Vice President Mike Pence told the graduates that religion in the United States is going strong."The percentage of Americans who live out their religion on a weekly basis ó praying...
Published: 05/17/18
Updated: 05/18/18
Column: Why baby steps toward cheaper drugs are the best we can do

Column: Why baby steps toward cheaper drugs are the best we can do

On the stump, Donald Trump the candidate promised big changes in the way America buys prescription drugs ó allowing Medicare to negotiate drug prices directly with pharmaceutical manufacturers, and allowing Americans to buy at the prices that Canada ...
Published: 05/15/18
Updated: 05/18/18
PolitiFact: Can Robert Mueller subpoena Donald Trump? A look at the legal precedents

PolitiFact: Can Robert Mueller subpoena Donald Trump? A look at the legal precedents

President Donald Trump has said heíd "love to speak" to special counsel Robert Mueller but that some of his lawyers advise against it.The latest member of Trumpís legal team, Rudy Giuliani, said Trump is under no obligation to comply with a subpoena ...
Published: 05/09/18
Updated: 05/13/18

Column: Moms looking out for daughters who need special medical treatment

Five years ago, shortly after celebrating Motherís Day, my mom watched as her oldest child was wheeled into brain surgery to undergo a procedure to help cope with the symptoms of early Parkinsonís disease. The operation, known as Deep Brain Stimulati...
Published: 05/09/18
Updated: 05/13/18
Column: As the last Rosewood survivor dies, letís remember our duty to address injustice

Column: As the last Rosewood survivor dies, letís remember our duty to address injustice

Mary Hall Daniels was a child of 3 when a white mob destroyed her home and the predominantly African-American community of Rosewood in Levy County in 1923. The last survivor of what came to be known as the Rosewood massacre, Mrs. Daniels died on May ...
Published: 05/08/18
Updated: 05/13/18
Perspective: Let’s build a ‘house’ for Kerouac in St. Pete ... (no not that one)

Perspective: Let’s build a ‘house’ for Kerouac in St. Pete ... (no not that one)

Over my writing desk is a pop-art image of Jack Kerouac. He is so handsome. In purple, orange, and shades of green, it shows him in his prime, a typewriter in the corner and his words about the people he loves, the ones who "burn, burn, burn like fab...
Published: 05/07/18
Updated: 05/13/18
Five interesting facts

Five interesting facts

$171.5 millionis how much drug makers spent lobbying the federal government last year, more than any other industry.Just 36%of Republicans last year thought free trade had been good for the United States, down from 57 percent in 2009, according to th...
Published: 05/07/18
Updated: 05/13/18
A Little Perspective: Interesting news and notes from around the world

A Little Perspective: Interesting news and notes from around the world

Another state has joined the National Popular Vote Interstate Compact, bringing electoral reformers closer to their goal of sidestepping the Electoral College to elect presidents by a nationwide popular vote instead. Under the compact, states pledge ...
Published: 05/03/18
Updated: 05/13/18